Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC documents for a research-stage biotech can be harder to navigate than the science itself. bioAffinity Technologies Inc., developer of the CyPath Lung non-invasive test, fills each report with flow-cytometry data, clinical protocols, and licensing notes. Finding trial milestones, R&D burn, or insider sentiment quickly is a real challenge—exactly the problem Stock Titan solves with bioAffinity Technologies SEC filings explained simply.
Our AI engine parses every submission from EDGAR in seconds, tags it by topic, and delivers the context you need:
- bioAffinity Technologies insider trading Form 4 transactions in minutes
- bioAffinity Technologies quarterly earnings report 10-Q filing distilled
- bioAffinity Technologies 8-K material events explained
- bioAffinity Technologies annual report 10-K simplified
- bioAffinity Technologies proxy statement executive compensation clearly shown
- bioAffinity Technologies Form 4 insider transactions real-time alerts
- bioAffinity Technologies earnings report filing analysis with trend charts
- understanding bioAffinity Technologies SEC documents with AI made easy
- bioAffinity Technologies executive stock transactions Form 4 mapped to announcements
Whether you’re monitoring insider buys before a clinical update, comparing quarter-over-quarter cash burn, or assessing how licensing revenue offsets trial costs, our platform keeps you informed. Real-time alerts, AI-written highlights, and original documents sit side by side, letting investors and healthcare analysts move from raw data to decisions in seconds—no more hunting through footnotes.
bioAffinity Technologies, Inc. disclosed that Nasdaq notified the company it failed to maintain the $1.00 minimum bid price for the period December 23, 2024 through February 6, 2025 and did not regain compliance by the 180-day cure deadline. The Listing Qualifications Staff also determined the company is ineligible for a second compliance period because its reported stockholders' equity of $1,439,404 as of March 31, 2025 is below Nasdaq's $2,500,000 minimum for continued listing.
The company was told its securities will be scheduled for delisting and suspended at the opening of business on August 18, 2025 unless it requests an appeal by August 14, 2025. bioAffinity intends to file an appeal to stay the suspension and will present its plan to regain compliance; hearings are typically scheduled ~30-45 days after a hearing request and the Panel typically issues a decision within ~30 days after the hearing. The filing also notes a press release announcing increased commercial sales of CyPath® Lung.
bioAffinity Technologies, Inc. (symbol BIAFW) has submitted a post-effective amendment on Form POS AM. The excerpt provided is almost entirely made up of XBRL tag references that map the company’s equity classes, incentive plans, warrants and other membership interests across various reporting periods. No narrative discussion, transaction description, or quantitative financial statements accompany the tags. As presented, the amendment appears to be an administrative update to existing registration statements—likely refreshing or re-labeling warrant-related securities—rather than announcing new capital raises or operational developments.
Because the filing lacks earnings data, cash-flow details, or material corporate actions, it offers no immediate insight into profitability, liquidity, or strategy. For investors, the document’s impact is therefore minimal unless later supplemented by a prospectus or pricing information that changes dilution expectations.
bioAffinity Technologies has filed a POS AM (Post-Effective Amendment) related to their warrant securities (BIAFW). The filing includes several key warrant-related developments:
- Multiple Warrant Offerings: The company has various warrant classes including tradeable and non-tradeable warrants, pre-IPO convertible notes, and placement agent warrants
- Recent Warrant Activity: Notable warrant transactions occurred in March 2024, August 2024, and October 2024, with additional warrant inducement events in February 2025
- Equity Incentive Plans: The company maintains both 2014 and 2024 equity incentive plans, including restricted stock units (RSUs) and stock options for employees, non-employees, and board members
- Financial Structure: The filing details the company's capital structure including common stock, preferred stock, and various warrant classifications with their respective terms and conditions
This amendment appears to update and clarify the terms and conditions of the company's outstanding warrants and related securities, ensuring compliance with SEC regulations and providing updated information to investors.
FAQ
What is the current stock price of bioAffinity Tech (BIAFW)?
